Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07525258

Enrollment

Registered

2026-04-13

Start date

2026-04-05

Completion date

2029-04-01

Last updated

2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol-associated Liver Disease, Alcohol Use Disorder

Keywords

Clinicians, Medications for Alcohol Use Disorder

Brief summary

The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.

Interventions

BEHAVIORALImplementation Intervention

A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Intervention model description

Hepatology clinicians including attending physicians, trainees, and advanced practice providers will be invited to participate in an implementation facilitation intervention to improve AUD treatment in hepatology clinics. The interventions will include education, patient materials, clinical decision support tools and coaching/feedback.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.

Exclusion criteria

* Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.

Design outcomes

Primary

Measure	Time frame	Description
Feasibility	12 months	Percentage of clinicians enrolled out of all recruited

Secondary

Measure	Time frame	Description
Acceptability	12 months	Percentage of clinicians that attend the educational workshops and utilize implementation tools.

Countries

United States

Contacts

CONTACTLamia Haque, MD MPH

lamia.haque@yale.edu(203) 777-0304

PRINCIPAL_INVESTIGATORLamia Haque

Yale University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026